Abstract
An impaired oesophageal clearance is characteristically found in children with CBPD (1). In a double-blind, placebo controlled cross-over setting, we studied the effect of the digestive prokinetic drug cisapride (CIS) in 14 infants and children with CPBD (median age : 29 months) by continuous monitoring of the lower oesophageal pH. CIS was dosed at 0.3 mg/kg 4 hours before the start of the measurements, followed by 3 times 0.15 mg/kg every 4 hours. Placebo (PLAG) administration was matched. Results show that, both during the total recording period and during sleep, the % time during which pH was < 4 (t4) and the No. of gastro-oesophageal (GOR) episodes of at least 5 minutes (N5) were significantly (p ≤ 0.05) reduced by CIS as compared to PLAC.Conclusion : CIS objectively reduces GOR in children, primarily by reducing the number of long duration GOR episodes, which characterize these patients. Clinical trials of CIS in children with CBPD seem justified.(1) C. Hoyoux, P. Forget, F. Geubelle. Pediatric Pulmonology 1:149-153, 1985.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
